The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2016 | Continuation of ceritinib beyond disease progression in ALK-positive NSCLC
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Enriqueta Felip, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses results from a retrospective study showing the continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
